Cormorant Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Cormorant Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,250,000	Closed	-$29.4M	–	67
2024 Q1	$29.4M	Hold	3,250,000	–	–	1.29%	25
2023 Q4	$35.3M	Buy	3,250,000 +625,000	+24%	+$4.68M	1.69%	17
2023 Q3	$21.1M	Buy	+2,625,000	New	+$21.8M	1.23%	23
2018 Q4	–	Sell	-75,000	Closed	-$3M	–	74
2018 Q3	$3M	Sell	75,000 -44,528	-37%	-$1.27M	0.2%	58
2018 Q2	$3.38M	Hold	119,528	–	–	0.25%	53
2018 Q1	$1.83M	Sell	119,528 -5,472	-4%	-$130K	0.14%	49
2017 Q4	$4.08M	Buy	+125,000	New	+$3.37M	0.43%	41

Other funds holding MRNS

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cormorant Asset Management's MRNS Position: Q2 2024 in Review

Cormorant Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 3,250,000 shares — an estimated $29.4M sold.

Cormorant Asset Management first reported a position in MRNS in Q4 2017 and held it in 7 quarters. The position peaked at $35.3M in Q4 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

Cormorant Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
Cormorant Asset Management sold 3,250,000 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $29.4M.
Cormorant Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 7 quarters.
Cormorant Asset Management's Marinus Pharmaceuticals, Inc position peaked at $35.3M in Q4 2023.
90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.